Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.

Coeptis paid $570,000 in cash to Deverra and provided four million shares from its common stock.

The deal allows Coeptis to strengthen its existing SNAP-CAR and GEAR technologies with two investigational new drug applications and two assets of Deverra that are currently undergoing Phase I clinical study.

The trial is investigating the infusion of unmodified natural killer (NK) cell therapy DVX201, produced from pooled donor CD34+ cells to treat haematologic malignancies and viral infections.

Coeptis will also add an allogeneic cellular immunotherapy platform that is being developed for producing and delivering off-the-shelf (without HLA matching) on-demand cell therapies.

Coeptis will also infuse clinical stage-ready allogeneic technologies into its pipeline assets. These will help in developing allogeneic-engineered NK and MAC cell therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Coeptis Therapeutics president and CEO Dave Mehalick stated: “Finalising this transaction represents a pivotal transition of Coeptis into a clinical-stage company with novel, synergistic and differentiated cell therapy pipeline candidates.

“As we move forward, I am excited to work with Colleen Delaney MD, a visionary scientist whose career has been dedicated to researching and advancing all aspects of cell therapy product development.

“A true leader in the field, Colleen’s experience and leadership will be invaluable as we progress our expanded pipeline towards our ultimate goal of bringing improved treatments to patients in need.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

This content was updated on 25 January 2024